Amber Bio

San Francisco, United States Founded: 2021 • Age: 5 yrs
CDMO focused on manufacturing generic drugs

About Amber Bio

Amber Bio is a company based in San Francisco (United States) founded in 2021 by Jacob Borrajo.. Amber Bio has raised $26 million across 1 funding round from investors including Lilly, Andreessen Horowitz and Retinal Degeneration Fund. Amber Bio offers products and services including RNA Writing Platform. Amber Bio operates in a competitive market with competitors including Novartis, Catalent, Curia, Surrozen and Biotage, among others.

  • Headquarter San Francisco, United States
  • Founders Jacob Borrajo
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $26 M (USD)

    in 1 rounds

  • Latest Funding Round
    $26 M (USD), Seed

    Aug 03, 2023

  • Investors
    Lilly

    & 5 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Amber Bio

Amber Bio offers a comprehensive portfolio of products and services, including RNA Writing Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Enables editing of thousands of genetic mutations with a single product.

People of Amber Bio
Headcount 1-10
Employee Profiles 3
Employee Profiles
People
Patty Biezonski
VP Of Development
People
Tou Lee
Lab Manager
People
Jacob Borrajo
Founder & CEO

Unlock access to complete

Funding Insights of Amber Bio

Amber Bio has successfully raised a total of $26M through 1 strategic funding round. The most recent funding activity was a Seed round of $26 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Seed — $26.0M
  • First Round

    (03 Aug 2023)

  • Investors Count 6
Date Amount Transaction Name Valuation Lead Investors Investors
Aug, 2023 Amount Seed - Amber Bio Valuation a16z
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Amber Bio

Amber Bio has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Andreessen Horowitz and Retinal Degeneration Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
Founded Year Domain Location
Investments are focused on retinal degeneration therapeutic solutions.
Founded Year Domain Location
Investments in early-stage startups are focused on by Hummingbird Ventures.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Amber Bio

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Amber Bio

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Amber Bio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Amber Bio

Amber Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novartis, Catalent, Curia, Surrozen and Biotage, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
R&D focused on manufacturing of drugs for multiple therapeutic areas
domain founded_year HQ Location
CDMO offering drug and biologics development services
domain founded_year HQ Location
Drug research, development, testing, and consulting services are provided.
domain founded_year HQ Location
Selective Wnt agonists are developed for human tissue regeneration.
domain founded_year HQ Location
Organic synthesis, analytical, and peptide chemistry services for drug discovery and development
domain founded_year HQ Location
Provides contract research, development, and manufacturing services for biologic drugs.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Amber Bio

Amber Bio Raises $26M in Seed Financing
Finsmes2 years ago

Frequently Asked Questions about Amber Bio

When was Amber Bio founded?

Amber Bio was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is Amber Bio located?

Amber Bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Who is the current CEO of Amber Bio?

Jacob Borrajo is the current CEO of Amber Bio. They have also founded this company.

Is Amber Bio a funded company?

Amber Bio is a funded company, having raised a total of $26M across 1 funding round to date. The company's 1st funding round was a Seed of $26M, raised on Aug 03, 2023.

What does Amber Bio do?

Amber Bio offers RNA Writing Platform while focusing on providing healthcare solutions, biopharma outsourcing, diversified, and biologics. CDMO focused on manufacturing generic drugs. Delivering reliable solutions, it emphasizes quality, efficiency, and meeting diverse client needs. It continues to evolve, meeting industry challenges with strategic approaches.

Who are the top competitors of Amber Bio?

Amber Bio's top competitors include Novartis, Surrozen and Catalent.

What products or services does Amber Bio offer?

Amber Bio offers RNA Writing Platform.

Who are Amber Bio's investors?

Amber Bio has 6 investors. Key investors include Lilly, Andreessen Horowitz, Retinal Degeneration Fund, Hummingbird Ventures, and Pillar VC.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available